FDA approves preventive migraine treatment

On Thursday, the US Food and Drug Administration approved Aimovig for the preventive treatment of migraines in adults with episodic or chronic migraines. Episodic migraine is when symptoms occur zero to 14 days each month; symptoms of chronic migraine occur 15 days or more a month.Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, or CGRP, a molecule that is involved in migraine attacks. Aimovig targets that molecule’s receptor in your body. The treatment, administered through monthly self-injections, requires a prescription and could be available to patients within a week. Aimovig is expected to cost $575 monthly or $6,900 annually in the United States.There are

Continue reading FDA approves preventive migraine treatment at CNN Health.



You Might Like
Learn more about RevenueStripe...

Bringing you breaking health news, tips & features on living better.